Seattle, WA 的 子宮內膜癌 臨床試驗
17 項針對 子宮內膜癌 的研究正在 Seattle(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Swedish Medical Center-First Hill, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Swedish Medical Center-First Hill, Seattle
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- Swedish Medical Center-First Hill, Seattle
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
招募中1/2 期
- Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
招募中2 期
- Swedish Medical Center First Hill, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- University of Washington Fred Hutchinson, Seattle
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
招募中2 期
- Swedish Cancer Center, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
招募中1 期
- Fred Hutchinson Cancer Center, Seattle
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Swedish Cancer Institute, Seattle
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
招募中3 期
- Research Site, Seattle
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Fred Hutchinson Cancer Center, Seattle
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- Fred Hutchinson Cancer Center, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Fred Hutchinson Cancer Center, Seattle
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
招募中2 期
- Swedish Cancer Institute, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Seattle
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Chicago, IL25 項研究
- Columbus, OH25 項研究
- Queens, NY25 項研究
Seattle 的其他研究
- 非小細胞肺癌53 項研究
- 癌症(所有類型)49 項研究
- 前列腺癌42 項研究
- 急性髓系白血病40 項研究
- 乳癌39 項研究
- 轉移性癌症39 項研究
- 大腸直腸癌34 項研究
- 肺癌33 項研究
- 卵巢癌30 項研究
- 多發性骨髓瘤22 項研究
- 骨髓增生異常症候群21 項研究
- 急性淋巴母細胞性白血病21 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月5日。各研究自行設定資格標準;由研究團隊決定參與者資格。